Provider Status for Pharmacists: Call to Action or Distant Dream?

By: Samantha Schmidt, PharmD Candidate c/o 2014, Palm Beach Atlantic University

The role of pharmacists in healthcare has grown exponentially over the years. Pharmacists now provide advanced patient-centered care services including coordination of medications during transitions of care, comprehensive medication reviews with medication monitoring, chronic disease management, disease education, prevention and wellness services, and patient education. Unfortunately, pharmacists are not listed as healthcare providers in the non-physician section of the Social Security Act, which deprives them of compensation for comprehensive patient-centered care under Medicare Part B.1 This omission impedes the integration of pharmacists into innovative healthcare delivery models like patient-centered medical homes (PCMH) and accountable care organizations (ACO), both of which are being brought forth by the Affordable Care Act (ACA).1

Proper medication use is essential to improve quality of life and to ensure that health outcomes are achieved in a cost-effective manner. In the United States, more than 1.5 million preventable medication-related adverse events occur every year.2 It costs Medicare, whose enrollees are people aged 65 and older, $887 million every year to treat preventable medication errors.2 Pharmacists have extensive education and training in the use of medications for the treatment, management, and prevention of disease and can be an essential part of the healthcare team.3 One simple tactic to improve patient outcomes and decrease costs is for pharmacists, working with physicians, to have a greater role in managing patients’ medications.3

Recently, Governor Jerry Brown of California signed a bill (SB 493) that establishes Advanced Practice Pharmacists (APP), giving new authorities to licensed pharmacists.1 SB 493 will allow APPs to perform patient assessments, order and interpret drug therapy, refer patients to other healthcare providers, and initiate, adjust, and discontinue drug therapy (according to established protocols with physicians).1 Although this bill does not address compensation, it is a major step toward provider status recognition for pharmacists.1 The American Pharmacists Association, along with other professional pharmacy organizations, needs each and every pharmacist and pharmacy student to take an active role in making this change. The time to act is now.

Please visit: http://www.pharmacist.com/providerstatusrecognition

SOURCES:

  1. American Pharmacists Association. Provider status: what pharmacists need to know now. Available at: http://www.pharmacist.com/provider-status-what-pharmacists-need-know-now. Updated September 2013. Accessed October 21, 2013.
  2. Institute of Medicine. Report brief: preventing medication errors. Available at: http://www.iom.edu/~/media/Files/Report%20Files/2006/Preventing-Medication-Errors-Quality-Chasm-Series/medicationerrorsnew.pdf. Updated July 2006. Accessed on October 21, 2013.
  3. Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. US pharmacists’ effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010;48:923–33.
eMAR

Recent Posts

Oxidative Stress and Its Impact on Vitiligo

By: Zurriya Faran, PharmD Candidate c/o 2031 The visible loss of skin pigmentation often indicates…

2 months ago

Thiamine Metabolic Dysfunction Syndrome: Overview, importance, MOA, and treatment

By: Archana Murugan, PharmD candidate c/o 2029 Overview             Thiamine metabolic dysfunction syndrome (TMDS) refers…

2 months ago

Updated Guidelines for the Treatment of Multidrug and Rifampin-Resistant TB and Promising New Anti-TB Drugs in Phase 2/3 Trials

By: Kevin Lee, PharmD Candidate c/o 2028, Angela Yin, PharmD Candidate c/o 2028             The…

2 months ago

Sixth Year Perspective: Interview with Ariella Zadrima, PharmD Candidate, c/o 2026

By: Aymon Choudhury, PharmD Candidate c/o 2027 APPE questions: How did your APPE rotations shape…

2 months ago

Foundayo: The New Drug in the GLP-1 market

By: Sariah Grant, PharmD Candidate c/o 2027             The rise of glucagon-like peptide -1 receptor…

2 months ago

Should All Drugs be OTC? Risks and Consequences of the FDA Commissioner Statement

By: Amanda Kastel, PharmD Candidate c/o 2027 In February 2026, FDA Commissioner Marty Makary stated…

2 months ago